Scientific Posters and Presentations

Categories

Year

May 29, 2026

Poster: Effect of Pemvidutide on Cardiovascular Risk Factors in Patients with MASH: 48-Week Results from the Phase 2b IMPACT Trial

Source

Tomah

EASL Congress

May 29, 2026

Poster: Concurrent Responses in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis Following Pemvidutide Treatment: 24-Week Responder Analyses from the Phase 2b IMPACT Trial

Source

Roberts

EASL Congress

May 28, 2026

Presentation: Week 48 Top-Line Results from the Phase 2b, Multicenter, Randomized, Placebo-Controlled IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis

Source

Noureddin

EASL Congress

May 27, 2026

Poster: Pemvidutide Treatment Led to Fibrosis Regression After 24 Weeks in Patients with MASH: Quantitative Digital Pathology Analysis from the Phase 2b IMPACT Trial

Source

Tomah

EASL Congress

Nov 11, 2025

Presentation: A Phase 2, Multicenter, Randomized, Placebo-Controlled Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis

Source

Noureddin

AASLD - The Liver Meeting®

Nov 07, 2025

Poster: Reduction of Liver Fibrosis by AI-Based Digital Pathology Analysis: Results from the Pemvidutide Phase 2b IMPACT Trial

Source

Gutierrez

AASLD - The Liver Meeting®

May 08, 2025

Poster: MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of metabolic dysfunction-associated steatohepatitis (MASH)

Source

Tomah

EASL International Liver Congress™

Dec 06, 2024

Presentation: Muscle Wasting in Weight Loss Therapy

Source

Harris

International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

Nov 15, 2024

Poster: Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Plasma Lipidomic Profiles in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Source

Browne

AASLD - The Liver Meeting®

Sep 25, 2024

Presentation: Unlocking Glucagon Biology to Overcome Fibrosis in MASH

Source

Harris

MASH Drug Development Summit

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Next page
Last page

Scientific
Posters and Presentations

Scientific Posters and Presentations

Investor Contact

Email Alerts

Altimmune

Pipeline

Investors

ScientificPosters and Presentations

Tabs Events and Presentations

Scientific Posters and Presentations

Investor Contact

Email Alerts

Nav ALTIMMUNE

Altimmune

Nav Pipeline

Pipeline

Nav IR

Investors

Social

Nav About Us

Nav Pipeline

Nav IR

Nav Clinical Trials

Nav Partnerships

Nav Contact

Scientific
Posters and Presentations